Figshare
open access
CC BY 4.0
Targeting CD38 in immune thrombocytopenia: Rationale and a scoping review of daratumumab
biomedical-and-clinical-sciencescardiovascular-medicine-and-haematologyclinical-sciencespharmacology-and-pharmaceutical-sciences
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors#234428
- A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)#1045007
- Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer#307306
- Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.#1096852
- Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors#855291
Record · ID 268283
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive